Multiple Sclerosis: Mechanisms and Immunotherapy

@article{BaecherAllan2018MultipleSM,
  title={Multiple Sclerosis: Mechanisms and Immunotherapy},
  author={Clare M. Baecher-Allan and Belinda J. Kaskow and Howard L. Weiner},
  journal={Neuron},
  year={2018},
  volume={97},
  pages={742-768}
}
View on Elsevier
cell.com
381 Citations
Highly Influential Citations
21
Background Citations
110
Methods Citations
5
Results Citations
4

Figures and Tables from this paper

381 Citations

Citation Type

Citation Type

Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
TLDR
An updated overview of the involvement of B cells in the immune pathophysiology and pathology of MS is provided, determining a shift from the traditional view of MS activity as largely being ‘T-cell mediated’ to the notion that MS-related pathological processes involve bi-directional interactions between several immune cell types, including B cells, both in the periphery and in the CNS.
Inflammatory mechanisms underlying cortical injury in progressive multiple sclerosis
TLDR
A better understanding of the interplay between peripheral immune and CNS resident cells is not only relevant to the concept of the disease process, but also represents a novel target for therapeutic intervention that is more specific to progressive disease biology.
Adoptive Transfer of Regulatory T Cells as a Promising Immunotherapy for the Treatment of Multiple Sclerosis
TLDR
Recent progress relating to adoptive transfer of regulatory T (Treg) cells in the treatment of human autoimmune disease is outlined, and the prospects of Treg adoptive cell transfer as a novel treatment in MS and associated symptoms are discussed.
Multiple sclerosis
TLDR
This Primer provides an overview of the immunopathology, diagnosis and management of multiple sclerosis, characterized by the formation of demyelination lesions throughout the central nervous system, leading to neurological dysfunction.
Multiple Sclerosis: Therapeutic Strategies on the Horizon
TLDR
The pathogenesis of MS, management of acute relapses, disease-modifying therapies in MS, new drugs and drugs currently in trial for MS and the symptomatic treatment of MS are discussed.
T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis
TLDR
The role and interplay of different Th cell subpopulations and their lineage-defining cytokines in modulating the inflammatory responses in MS and the approved as well as the novel therapeutic approaches targeting T lymphocytes in the treatment of the disease are discussed.
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
TLDR
A B-cell-depleting monoclonal antibody has recently been approved for MS therapy and is efficacious not only in relapsing forms of MS but also in some patients with primary progressive MS, suggesting that B cells may play a more important role in the pathogenesis of MS than previously appreciated.
Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
TLDR
Mechanisms of action involved in therapeutic efficacy as well as in PML risk will be discussed, and the interest of a biological monitoring that may be helpful to rapidly adapt treatment is presented.
The Histamine and Multiple Sclerosis Alliance: Pleiotropic Actions and Functional Validation.
TLDR
How a long-standing molecule with previously recognized immunomodulatory and neuroprotective functions, histamine, might still provide a renewed and far-reaching role in MS is reported on.
Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
TLDR
This review analyzes current MS treatments as well as different cell-based therapies that have been proposed to restore homeostasis in MS patients (tolerogenic dendritic cells, regulatory T cells, mesenchymal stem cells, and vaccination with T cells).
...
...

References

SHOWING 1-10 OF 293 REFERENCES
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis
TLDR
In patients with relapsing forms of MS, natalizumab therapy is known to significantly reduce intrathecal inflammatory responses which results in reductions in brain lesions and brain atrophy as well as beneficial effects on clinical measures, such as reduced frequency and severity of relapse and reduced accumulation of disability.
Progressive multiple sclerosis: from pathogenic mechanisms to treatment.
TLDR
Mechanisms involved in progressive multiple sclerosis, correlations between histopathology and magnetic resonance imaging studies, along with possible new therapeutic approaches are discussed.
Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response1
TLDR
Results demonstrate abnormalities of DCs in MS and may explain the immunologic basis for the different stages and clinical patterns of MS.
Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation
TLDR
No signature cytokines or profiles thereof are found in MS patients at presentation, and the parameters that distinguished MS patients from patients with other neurological disorders were IgG intrathecal synthesis, the IgG index and its correlation with CSF IL-4 levels.
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
TLDR
At a given time point of the disease, the patterns of demyelination were heterogeneous between patients, but were homogenous within multiple active lesions from the same patient, suggesting that MS may be a disease with heterogeneous pathogenetic mechanisms.
Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets
TLDR
The goal of this review is to summarize how B-cells may contribute to MS pathogenesis and thereby provide a basis for understanding why B-cell depletion is so effective in the treatment of this disease.
Multiple sclerosis: Atacicept increases relapse rates in multiple sclerosis
  • E. Bible
  • Biology, Medicine
    Nature Reviews Neurology
  • 2014
TLDR
In patients with MS, depletion of B-cell populations through targeting of the CD20 receptor with monoclonal antibodies such as rituximab or ocreluzimab has been shown to reduce both the frequency of relapses and the numbers of inflammatory lesions on MRI.
Disease-modifying treatments for progressive multiple sclerosis
  • G. Comi
  • Psychology, Medicine
    Multiple sclerosis
  • 2013
TLDR
An up-to-date overview of the rationale and results of the published clinical trials that have sought to alter the trajectory of both primary and secondary MS, considering studies involving drugs with a primary immune target and also those aiming for neuroprotection.
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Multiple sclerosis: Prospects and promise
TLDR
MS has now advanced from the backwaters of autoimmune disease research to the front‐line, and definitive answers, including cures, are now realistic goals for the next decade.
...
...